| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3269f865b719fd144a5a8ba7055b561f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2306
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 |
| filingDate |
2016-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35998ae80b335055836ebea775c1f610
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_626648947e8deb6ceeb7c59b215314da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b5ff15ad80450d63e0b3143659a5841 |
| publicationDate |
2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016304837-A1 |
| titleOfInvention |
Method of ex vivo expanding hematopoietic stem/ progenitor cells and the composition produced thereby |
| abstract |
The present invention relates to a process for rapidly ex vivo expanding and harvesting high-purity of hematopoietic stem/progenitor cells and the pharmaceutical composition comprising the same. The process of the present invention is characterized by: an overnight culture of mononuclear cells isolated by density gradient centrifugation; and subsequent purification and ex vivo expansion of high-purity hematopoietic stem/progenitor cells. The prepared hematopoietic stem/progenitor cells comprise high percentage of clinically effective hematopoietic stem/progenitor cells (the CD34 + CD38 − cells), and still maintain high viability and effective differential activity after cryopreservation and thawing processes. Besides, for the manufacturing method of the present invention does not use components of animal origin, the harvested hematopoietic stem/progenitor cells can be directly used in clinical applications. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10456423-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10213463-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11369640-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10426796-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10363271-B2 |
| priorityDate |
2015-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |